{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:57:30Z","timestamp":1763564250043,"version":"3.40.5"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Several innovative drugs liable to lead to changes in healthcare organization are or soon will be available for the management of hemophilia. Analyzing their implementation can shed further light on healthcare decision-making, to anticipate changes and risk of breakdown in the patient\u2019s care pathway.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>Multiple criteria decision analysis (MCDA), based on ISPOR recommendations, was used to assess the organizational impact of innovation in hemophilia care management. The MCDA process designed for this specific context involved ten French experts in hemophilia care management (physicians, nurses, pharmacist, physiotherapist and psychologist) in the hemophilia care center of Chamb\u00e9ry, in the Rh\u00f4ne-Alpes Region of France. This pilot study involved seven steps: (i) defining the decision problem; (ii) selecting and structuring criteria; (iii) assessing the relative weight of each criterion with software-assisted simulation based on pairwise comparisons of different organizational change scenarios; (iv) measuring the performance of the selected innovations; (v) scoring alternatives; (vi) calculating aggregate scores; (vii) discussion. The endpoint was to determine the expected overall organizational impact on a 0\u2013100 scale.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>Seven organizational criteria were selected. \"Acceptability for patient\/caregiver\/association\" was the most heavily weighted. Factor VIII by subcutaneous route obtained the highest aggregate score: i.e., low impact on care organization (88.8 out of 100). The innovation with strongest organizational impact was gene therapy (27.3 out of 100).<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusion<\/jats:title><jats:p>This approach provided a useful support for discussion, integrating organizational aspects in the treatment decision-making process, at healthcare team level. The study needs repeating in a few years\u2019 time and in other hemophilia centers.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0273775","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T20:33:15Z","timestamp":1662755595000},"page":"e0273775","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multiple criteria decision analysis for therapeutic innovations in a hemophilia care center: A pilot study of the organizational impact of innovation in hemophilia care management"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1437-4276","authenticated-orcid":true,"given":"Karen","family":"Beny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Dubromel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"du Sartz de Vigneulles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Carrouel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Negrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Dussart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"issue":"1","key":"pone.0273775.ref001","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"A Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"1","key":"pone.0273775.ref002","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ajh.26018","article-title":"2021 clinical trials update: Innovations in hemophilia therapy","volume":"96","author":"SE Croteau","year":"2021","journal-title":"American Journal of Hematology"},{"issue":"4","key":"pone.0273775.ref003","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A Molecular Revolution in the Treatment of Hemophilia","volume":"28","author":"JSS Butterfield","year":"2020","journal-title":"Molecular Therapy"},{"issue":"Suppl 6","key":"pone.0273775.ref004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/hae.13510","article-title":"Emerging therapies for haemophilia\u2014Global perspective","volume":"24","author":"J Mahlangu","year":"2018","journal-title":"Haemophilia"},{"issue":"10274","key":"pone.0273775.ref005","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"ME Mancuso","year":"2021","journal-title":"The Lancet"},{"issue":"1","key":"pone.0273775.ref006","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/16078454.2019.1687798","article-title":"Re-personalization and stratification of hemophilia care in an evolving treatment landscape","volume":"24","author":"DP Hart","year":"2019","journal-title":"Hematology"},{"issue":"493","key":"pone.0273775.ref007","first-page":"25","article-title":"Research and innovation: nine ways for the successful introduction of medical innovations","author":"E. Fery-Lemonnier","year":"2003","journal-title":"Rev hosp Fr (Paris)"},{"issue":"11","key":"pone.0273775.ref008","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.healthpol.2015.08.011","article-title":"Hospital managers\u2019 need for information in decision-making\u2013An interview study in nine European countries","volume":"119","author":"K Kidholm","year":"2015","journal-title":"Health Policy"},{"issue":"4","key":"pone.0273775.ref009","doi-asserted-by":"crossref","first-page":"e0231571","DOI":"10.1371\/journal.pone.0231571","article-title":"Multiple criteria decision analysis approach to consider therapeutic innovations in the emergency department: The methoxyflurane organizational impact in acute trauma pain","volume":"15","author":"VE Lvovschi","year":"2020","journal-title":"PLOS ONE"},{"issue":"8","key":"pone.0273775.ref010","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jval.2012.06.015","article-title":"Multiple Criteria Decision Analysis for Health Technology Assessment","volume":"15","author":"P Thokala","year":"2012","journal-title":"Value in Health"},{"issue":"6","key":"pone.0273775.ref011","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s13593-020-00650-3","article-title":"Diversity and potentiality of multi-criteria decision analysis methods for agri-food research","volume":"40","author":"G G\u00e9san-Guiziou","year":"2020","journal-title":"Agron Sustain Dev"},{"key":"pone.0273775.ref012","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40070-016-0060-x","article-title":"Renewables in the UE after 2020: a multi-criteria decision analysis in the context of the policy formation process","volume":"4","author":"S Steinhilber","year":"2016","journal-title":"EURO J Decis Process"},{"issue":"3","key":"pone.0273775.ref013","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ejor.2007.11.020","article-title":"A possibilistic-valued multi-criteria decision-making support for marketing activities in e-commerce: Feedback Based Diagnosis System","volume":"195","author":"A Denguir-Rekik","year":"2009","journal-title":"European Journal of Operational Research"},{"issue":"1\u20112","key":"pone.0273775.ref014","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.orhc.2013.03.001","article-title":"Multi-criteria decisin analysis (MCDA) in health care: a bibliometric analysis","volume":"2","author":"V Diaby","year":"2013","journal-title":"Operations research for health care"},{"issue":"1","key":"pone.0273775.ref015","doi-asserted-by":"crossref","first-page":"1360545","DOI":"10.1080\/20016689.2017.1360545","article-title":"Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016","volume":"5","author":"JI Drake","year":"2017","journal-title":"Journal of Market Access & Health Policy"},{"issue":"4","key":"pone.0273775.ref016","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1017\/S0266462320000525","article-title":"Can multi-criteria decision analysis (MCDA) be implemented into real-world drug decision-making processes? A Canadian provincial experience","volume":"36","author":"T-L Laba","year":"2020","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"pone.0273775.ref017","unstructured":"Organisational impact map for health technology assessment [Internet]. Haute Autorit\u00e9 de Sant\u00e9; 2020 [cited 18 juill 2021]. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-04\/organisational_impact_map_for_health_technology_assessment.pdf"},{"key":"pone.0273775.ref018","unstructured":"Sullivan T. Using MCDA (Multi-Criteria Decision Analysis) to prioritise publicly-funded health care. [Th\u00e8se de docorat]. [Dunedin, New Zealand]: University Of Otago; 2012."},{"issue":"3\u20114","key":"pone.0273775.ref019","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mcda.428","article-title":"A New method For scoring Additive multi-attribute value models using pairwise rankings of alternatives","volume":"15","author":"P Hansen","year":"2008","journal-title":"J Multi-Criteria Decis Anal"},{"key":"pone.0273775.ref020","unstructured":"1000minds [Internet]. [cit\u00e9 le 9 ao\u00fbt 2017]. Disponible \u00e0: https:\/\/www.1000minds.com"},{"key":"pone.0273775.ref021","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40261-021-01108-4","article-title":"Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting","volume":"42","author":"G. Gourzoulidis","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"S6","key":"pone.0273775.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"pone.0273775.ref023","article-title":"Chronic pain, a complex situation model","author":"G Mick","year":"2017","journal-title":"Douleur analg"},{"issue":"1","key":"pone.0273775.ref024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","article-title":"Multiple Criteria Decision Analysis for Health Care Decision Making \u2010 An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force","volume":"19","author":"P Thokala","year":"2016","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"4","key":"pone.0273775.ref025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40273-014-0135-0","article-title":"Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature","volume":"32","author":"K Marsh","year":"2014","journal-title":"PharmacoEconomics"},{"issue":"2","key":"pone.0273775.ref026","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/ijerph19020646","article-title":"Haemophilia in France: Modelisation of the Clinical Pathway for Patients","volume":"19","author":"K. Beny","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"pone.0273775.ref027","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/13543784.2020.1722999","article-title":"Investigational drugs to treat hemophilia","volume":"29","author":"M Franchini","year":"2020","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"5","key":"pone.0273775.ref028","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","article-title":"New therapies using nonfactor products for patients with hemophilia and inhibitors","volume":"133","author":"K Nogami","year":"2019","journal-title":"Blood"},{"issue":"1","key":"pone.0273775.ref029","doi-asserted-by":"crossref","first-page":"1810905","DOI":"10.1080\/20016689.2020.1810905","article-title":"Organizational aspect in healthcare decision-making: a literature review","volume":"8","author":"A Dubromel","year":"2020","journal-title":"Journal of Market Access & Health Policy"},{"key":"pone.0273775.ref030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13023-020-01456-y","article-title":"Evolution of Haemophilia Care in Europe: 10 Years of the Principles of Care","volume":"15","author":"D. Noone","year":"2020","journal-title":"Orphanet J. Rare Dis"},{"key":"pone.0273775.ref031","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2516.2010.02362.x","article-title":"Haemophilia Care in Europe: A Survey of 19 Countries","volume":"17","author":"B. O\u2019Mahony","year":"2011","journal-title":"Haemophilia"},{"key":"pone.0273775.ref032","unstructured":"Chamouard V. Negrier C. Cabon M, et al. Sch\u00e9ma de coordination entre les intervenants pour l\u2019accompagnemant de la dispensation d\u2019emicizumab en pharmacie d\u2019officine. MHEMO. 2021 Jun 8. Available from: https:\/\/mhemo.fr\/actualites\/accompagnement-de-linstauration-dun-double-circuit-de-dispensation-demicizumab-en-pharmacie-de-ville-et-a-lhopital\/. French."},{"issue":"1","key":"pone.0273775.ref033","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/hae.14190","article-title":"Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study","volume":"27","author":"E van Overbeeke","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"pone.0273775.ref034","first-page":"1","article-title":"Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study","volume":"16","author":"DP Hart","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"pone.0273775.ref035","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/hae.13769","article-title":"How to discuss gene therapy for haemophilia? A patient and physician perspective","volume":"25","author":"W Miesbach","year":"2019","journal-title":"Haemophilia"},{"issue":"6","key":"pone.0273775.ref036","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/hae.13830","article-title":"Patient-centred care in haemophilia: Patient perspectives on visualization and participation in decision-making","volume":"25","author":"EC van Balen","year":"2019","journal-title":"Haemophilia"},{"key":"pone.0273775.ref037","unstructured":"Srivastava S. How Cell And Gene Therapy Is Transforming Healthcare. Cellandgene. 2020 Feb 4. Available from: https:\/\/www.cellandgene.com\/doc\/how-cell-and-gene-therapy-is-transforming-healthcare-0001"},{"key":"pone.0273775.ref038","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/hae.14420","article-title":"Delivery of AAV-based gene therapy through haemophilia centres-A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC","volume":"27","author":"W Miesbach","year":"2021","journal-title":"Haemophilia"},{"key":"pone.0273775.ref039","unstructured":"Athanasopoulos A. Statement on Gene Therapies Hub-and-Spoke Model. EAHAD\u2013EHC. 2020 May 20. Available from: https:\/\/eahad.org\/eahad-ehc-statement-on-promoting-hub-and-spoke-model-using-gene-therapies\/"},{"key":"pone.0273775.ref040","unstructured":"Dubromel A. [Taking into account the organizational impact of a health innovation: example of a clinical pathway for a diabetic patient with macular edema] [dissertation]. Lyon (FR): Claude Bernard Lyon 1 University; 2017. Available from: https:\/\/www.sudoc.fr\/233290486. French."},{"issue":"2","key":"pone.0273775.ref041","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jval.2015.12.016","article-title":"Multiple Criteria Decision Analysis for Health Care Decision Making\u2014Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force","volume":"19","author":"K Marsh","year":"2016","journal-title":"Value in Health"},{"key":"pone.0273775.ref042","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2147\/PPA.S322531","article-title":"Patients\u2019 Perception of the Impact of Innovation on Hemophilia Care Management Organization: A Qualitative Study Protocol (INNOVHEMO Study)","volume":"15","author":"K Beny","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"pone.0273775.ref043","unstructured":"Martelli N. [Assessment of innovative medical devices in university hospitals with a view to their acquisition: inventory and development of a decision support tool]. Thesis, University Paris Sud\u2014Paris XI; 2015. Available from: https:\/\/tel.archives-ouvertes.fr\/tel-01158923"},{"issue":"1","key":"pone.0273775.ref044","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1472-6963-8-270","article-title":"Evidence and Value: Impact on DEcisionMaking\u2013the EVIDEM framework and potential applications","volume":"8","author":"MM Goetghebeur","year":"2008","journal-title":"BMC Health Services Research"},{"issue":"4","key":"pone.0273775.ref045","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1017\/S0266462312000487","article-title":"Development and test of a decision support tool for hospital health technology assessment","volume":"28","author":"L Sampietro-Colom","year":"2012","journal-title":"Int J Technol Assess Health Care"},{"issue":"6","key":"pone.0273775.ref046","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10198-019-01052-3","article-title":"Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art","volume":"20","author":"MD Oliveira","year":"2019","journal-title":"Eur J Health Econ"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T20:04:21Z","timestamp":1701029061000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273775"}},"subtitle":[],"editor":[{"given":"Wolfgang","family":"Miesbach","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0273775","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,9,9]]}}}